Clinical Trial Update: Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Plozasiran (ARO-APOC3) in adults with mixed dyslipidemia has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Dyslipidemia

Drugs mentioned

• Plozasiran

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Mixed Dyslipidemia | Phase 2 | Status: COMPLETED | Results posted: 2026-02-24